Please login to the form below

Not currently logged in
Email:
Password:

Hanmi

This page shows the latest Hanmi news and features for those working in and with pharma, biotech and healthcare.

Merck enters agreement with Hanmi for investigational NASH drug

Merck enters agreement with Hanmi for investigational NASH drug

In 2015,   J&J and Hanmi entered an alliance to develop efinopegdutide to treat diabetes and obesity, with Hanmi receiving an upfront payment of $105m for the drug. ... The deal with Hanmi builds on Merck’s existing NASH pipeline, which includes a mid

Latest news

More from news
Approximately 4 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2016 Deal Watch October 2016

    Hanmi (SK) / Jul 15. Boehringer Ing. (DE). Olmuntinib / Lung cancer.

  • Deal Watch September 2016 Deal Watch September 2016

    No financial terms were disclosed. Genentech signed an exclusive licence [global excluding South Korea] with Hanmi Pharmaceutical to develop and market HM95573, a pan-RAF inhibitor. ... 1, 000+. Hanmi / Genentech. Licence. HM95573, a selective

  • Deal Watch November 2015 Deal Watch November 2015

    $900m of which two were with the same company, Hanmi Pharmaceutical, a Korean public company. ... Option to co-develop/co-commercialise EU/US. 1, 560. Hanmi Pharmaceutical. Janssen Pharmaceuticals. Licence.

  • Medius Deal Watch table for March 2015 Medius Deal Watch table for March 2015

    750. Hanmi / Eli Lilly. Licence and collaboration. Phase 1 BTK inhibitor for treatment of lupus.

  • Pharma deals in March 2015 Pharma deals in March 2015

    Lilly's expedition to the Far East also generated another deal this month, the licence of a phase 1 BTK inhibitor from the Korean company Hanmi for up to $690m.

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics